LTR Pharma (ASX:LTP) EBITDA Margin %: -8,198.65% (As of Dec. 2025)


ASX:LTP LTR Pharma Ltd ASX:LTP
15 GF Score
Price A$0.56
! 1 Warning Sign
View Full Analysis

What is LTR Pharma EBITDA Margin %?

LTR Pharma ASX:LTP -4.27% 15 EBITDA Margin % is -8,198.65% as of Dec. 2025. GuruFocus rates ASX:LTP with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, LTR Pharma ranks worse than 91% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. LTR Pharma's EBITDA for the six months ended in Dec. 2025 was A$-6.07 Mil. LTR Pharma's Revenue for the six months ended in Dec. 2025 was A$0.07 Mil. Therefore, LTR Pharma's EBITDA margin for the quarter that ended in Dec. 2025 was -8,198.65%.

LTR Pharma  (ASX:LTP) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

LTR Pharma EBITDA Margin % Related Terms

LTR Pharma EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for LTR Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma EBITDA Margin % Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
EBITDA Margin %
0.00 0.00 0.00 0.00 -3,829.45

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial 0.00 0.00 -4,411.11 -3,387.95 -8,198.65

ASX:LTP vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, LTR Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LTR Pharma EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where LTR Pharma's EBITDA Margin % falls into.


ASX:LTP
15GF Score
LTR Pharma Ltd ASX:LTP
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LTR Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

LTR Pharma's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-5.591/0.146
=-3,829.45 %

LTR Pharma's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-6.067/0.074
=-8,198.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -8,198.65% mean?
LTR Pharma (ASX:LTP) has a EBITDA Margin % of -8,198.65% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on LTR Pharma and its competitors. According to the industry distribution chart, LTR Pharma ranks #859 out of 944 companies in the Biotechnology industry, placing it in the top 91%.
Is LTR Pharma's EBITDA Margin % too high?
LTR Pharma's current EBITDA Margin % is -8,198.65%. Based on the distribution chart, LTR Pharma ranks #859 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, LTR Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does LTR Pharma's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, LTR Pharma ranks #859 out of 944 companies for EBITDA Margin %. This places LTR Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on LTR Pharma and its competitors. LTR Pharma's current EBITDA Margin % is -8,198.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LTR Pharma stock overvalued right now?
LTR Pharma (ASX:LTP) has a current EBITDA Margin % of -8,198.65%. The current EBITDA Margin % is -8,198.65%. LTR Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For LTR Pharma (ASX:LTP), the current EBITDA Margin % is -8,198.65% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LTR Pharma Business Description

Address 9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
15GF Score

Get the complete analysis for ASX:LTP

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.56
Price